Targeting tumor angiogenesis with histone deacetylase inhibitors: The hydroxamic acid derivative LBH589

Medicine & Life Sciences

• Hydroxamic Acids 100%
• Panobinostat 98%
• Histone Deacetylase Inhibitors 72%
• Acetylation 24%
• Neoplasms 19%
• matrigel 17%
• Human Umbilical Vein Endothelial Cells 16%
• Cell Proliferation 15%
• Histones 14%
• G2 Phase Cell Cycle Checkpoints 10%
• PC-3 Cells 9%
• Angiogenesis Inhibitors 9%
• Mitogen-Activated Protein Kinase 3 9%
• Mitogen-Activated Protein Kinase 1 8%
• Chemokine Receptors 8%
• Proteins 8%
• Tubulin 8%
• Heterografts 6%
• Reverse Transcription 6%
• In Vitro Techniques 6%
• Prostate 6%
• Cell Cycle 6%
• Cell Survival 5%
• Endothelial Cells 5%
• Phosphorylation 5%
• Western Blotting 5%
• Carcinoma 5%
• Apoptosis 4%
• Gene Expression 4%
• Polymerase Chain Reaction 4%
• Blood Vessels 4%
• Growth 3%
• Therapeutics 2%